Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data
Open Access
- 17 February 2026
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 406-420
Abstract
Early detection of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis (CC) is critical for improving prognosis. The GAAD algorithm (gender [biological sex], age, alpha-fetoprotein [AFP], protein induced by vitamin K absence-II [PIVKA-II]) demonstrated good performance for the detection of early-stage HCC. This study aimed to assess the cost-effectiveness of the GAAD algorithm for HCC surveillance in patients with CC in Italy, from the Italian Health Service perspective. A probabilistic micro-simulation Markov model was adapted to the Italian context to estimate lifetime clinical outcomes and costs of CC patients undergoing bi-annual surveillance with ultrasound (US), US+AFP, GAAD, and US+GAAD. Clinical inputs and utility values were derived from Italian real-world data and published literature. Direct healthcare costs were collected from Italian sources. Costs and outcomes were discounted at an annual 3% rate. Sensitivity analyses were conducted to evaluate the uncertainties in input parameters. In a simulated cohort of 100,000 CC patients, QALYs and costs per patient were 6.53 and €35,524 for US, 6.56 and €35,825 for US+AFP, 6.57 and €35,423 for GAAD, and 6.58 and €35,939 for US+GAAD. Compared to US and US+AFP, GAAD was dominant, while US+GAAD was cost-effective (ICUR of €9,482 and €10,951 per QALY gained, respectively). At a willingness-to-pay threshold of €30,000, GAAD was the most cost-effective strategy. Sensitivity analyses confirmed the robustness of results. Assumptions were required to estimate the diagnostic performance of US+GAAD, given the absence of prospective validation data. Some clinical parameters were derived from non-Italian sources, which may limit generalizability. GAAD, alone or combined with US, is a cost-effective strategy for HCC surveillance in CC patients in Italy, improving the detection of early-stage disease. Better performance data for US+GAAD is needed to confirm results.Keywords
Funding Information
- Roche Diagnostics
This publication has 58 references indexed in Scilit:
- Novel insights into HBV‐hepatocellular carcinoma at single‐cell sequencingMedComm – Oncology, 2023
- NAFLD‐related hepatocellular carcinoma: The growing challengeHepatology, 2022
- Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular CarcinomaJAMA Network Open, 2021
- Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?Current Hepatology Reports, 2019
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseHepatology, 2017
- Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in ItalyThe European Journal of Health Economics, 2016
- Prognosis of untreated hepatocellular carcinomaHepatology, 2014
- Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinomaHepatology, 2013
- Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptorIUBMB Life, 2012
- Randomized controlled trial of screening for hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2004